Background/aim. Endogenous cannabinoids (ECs) include anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Recently, novel EC-related molecules have been discovered, i.e. oleoyl-ethanolamine (OEA) and palmitoyl-ethanolamine (PEA). AEA has been implicated in the pathogenesis of cardiovascular alterations in experimental cirrhosis, but the data in humans are sporadic and limited to AEA. Thus, we assessed whether: (1) the EC system is up-regulated in cirrhosis by comparing plasma and liver EC levels in cirrhotic pts and controls; (2) the cirrhotic liver contributes to the circulating EC by measuring their concentrations in brachial and hepatic veins; and (3) the EC levels correlate with systemic hemodynamics, portal pressure, liver and renal functions.
Caraceni P, D.M. (2009). Endocannabinoids and endocannabinoid-related molecules in patients with liver cirrhosis. DIGESTIVE AND LIVER DISEASE, 41(3), 14-14 [10.1016/j.dld.2008.12.031].
Endocannabinoids and endocannabinoid-related molecules in patients with liver cirrhosis
Caraceni P;Domenicali M
;Giannone F;Berzigotti A;Cescon M;Golfieri R;Zoli M;Bernardi M.
2009
Abstract
Background/aim. Endogenous cannabinoids (ECs) include anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Recently, novel EC-related molecules have been discovered, i.e. oleoyl-ethanolamine (OEA) and palmitoyl-ethanolamine (PEA). AEA has been implicated in the pathogenesis of cardiovascular alterations in experimental cirrhosis, but the data in humans are sporadic and limited to AEA. Thus, we assessed whether: (1) the EC system is up-regulated in cirrhosis by comparing plasma and liver EC levels in cirrhotic pts and controls; (2) the cirrhotic liver contributes to the circulating EC by measuring their concentrations in brachial and hepatic veins; and (3) the EC levels correlate with systemic hemodynamics, portal pressure, liver and renal functions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.